Lannett Receives Approval For Niacin Extended-Release Tablets USP, 500 Mg And 1000 Mg

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Infudopa SubC Parkinsons Therapy: Neuraxpharm-Dizlin Deal

Neuraxpharm Group (“Neuraxpharmâ€), a leading European specialty pharmaceutical company...

HALEON APPOINTS CARL HANEY AS CHIEF R&D OFFICER

Haleon today announces the appointment of Carl Haney as...

API China 2025 Concludes with Strong Turnout and Industry-Wide Momentum

Asia’s leading pharma show draws 200,000 visits and nearly...

Lannett Company Inc announced that it received approval from the U.S. FDA of its Abbreviated New Drug Application (ANDA) for Niacin Extended-Release Tablets USP, 500 mg and 1000 mg, the therapeutic equivalent to the reference listed drug, Niaspan® Extended-Release Tablets, 500 mg and 1000 mg, of AbbVie Inc.  

For the 12 months ended April 2017, total U.S. sales of Niacin Extended-Release Tablets USP, 500 mg and 1000 mg, at Average Wholesale Price (AWP) were approximately $152 million, according to IMS.

“Niacin Extended-Release Tablets is our second approval in recent days, setting the stage as we head into fiscal 2018,” said Arthur Bedrosian, chief executive officer of Lannett.  “This approval comes from our wholly owned subsidiary, Kremers Urban Pharmaceuticals, and will further diversify our product offering.  We anticipate launching our product shortly and continue to believe additional approvals are forthcoming.”

About Lannett Company, Inc.:
Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.  For more information, visit the company’s website at www.lannett.com

Robert Jaffe
Robert Jaffe Co., LLC
(424) 288-4098

Latest stories

Related stories

Infudopa SubC Parkinsons Therapy: Neuraxpharm-Dizlin Deal

Neuraxpharm Group (“Neuraxpharmâ€), a leading European specialty pharmaceutical company...

HALEON APPOINTS CARL HANEY AS CHIEF R&D OFFICER

Haleon today announces the appointment of Carl Haney as...

API China 2025 Concludes with Strong Turnout and Industry-Wide Momentum

Asia’s leading pharma show draws 200,000 visits and nearly...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back